El.En. SpA: receives FDA clearance for SMARTLIPO™ system for laser lipolysis

Firenze, November 10, 2006 – El.En. SpA, leader in the laser market and listed on the Star segment of the Italian Stock Exchange announced it has received clearance from the U.S. Food and Drug Administration for its Smartlipo™ system.

The system, already available for sale in selected countries through the controlled company DEKA M.E.L.A., will be distributed in North America by the controlled company Cynosure Inc. (NASDAQ:CYNO).

Through the disruption fat cells and the coagulation of microvases, the procedure allows optimal tissue remodeling and skin tightening. The Smartlipo system provides to aesthetic medicine a new, minimally invasive method for reducing fat cells.

DEKA reports that demand for liposuction and body sculpting procedures that remove or reduce fat cells is increasing. For example, nearly 500,000 liposuction procedures were performed in the U.S. in 2005.

I believe that the Smartlipo system is particularly useful for treating areas with localized fat deposits. In addition to disrupting fat, it coagulates and tightens tissue,” said Bruce Katz, MD, Clinical Professor at Mt. Sinai School of Medicine and Medical Director of JUVA Skin and Laser Center in New York City. “We have seen excellent results with this new laser lipolysis procedure."

“ The Smartlipo laser lipolysis is a minimally invasive procedure that is well suited for the treatment of small areas,” said Karen Kim, MD, a board-certified dermatologist at the Laser Skin and Surgery Center of New York. “Our early clinical trials suggest that patients experience rapid healing with little tissue trauma. Post-operative results can be seen as soon as one week, with continued improvement over several months.”

El.En. believes that the received clearance will not have material impact on the financial guidance previously released for the year 2006.

El.En., an Italian company, is the parent of a high-tech industrial group operating in the optoelectronics sector. Based on proprietary technology and multidisciplinary know-how, the El.En Group manufactures laser sources (gas, semiconductor, solid-state and liquid) and innovative laser systems for medical and industrial applications. The El.En. Group is the laser market leader in Italy and among the top operators in Europe. It designs, manufactures and sells worldwide:
- Medical laser equipment used in dermatology, cosmetics, physiotherapy, dentistry and gynecology;
- Industrial laser systems for applications ranging from cutting, marking and welding metals, wood, plastic and glass to decorating leather and textiles and restoring/conserving artwork;
- Laser systems for scientific research

EL.EN has been listed on the Star (MTAX) of Borsa Italiana. Its market floatation is approximately 23% and its market capitalization amounts to €130 million.
Cod. ISIN: IT0001481867
Code: ELN
Listed on MTAX
Mkt capt.: 130 mln/Euro
Cod. Reuters: ELN.MI
Cod. Bloomberg: ELN IM

For further information:

**El.En. SpA**
Enrico ROMAGNOLI
Investor Relator
Tel. +39-055-8826807
finance@elen.it

**Polytems HIR**
Rita CAMELLI
Press Office
Tel. +39-02-72093955; 335 439571
f.camelli@polytemshir.it

**Polytems HIR**
Bianca FERSINI MASTELLONI
Financial Communication
Tel.+39-06-6797849 ; +39-06-69923324
b.fersini@polytemshir.it